Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

By S. Tong, Joshua S. Davis, E. Eichenberger, T. Holland, V. Fowler. Clinical Microbiology Reviews, 2015

4,265 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pathogenicity and virulence of Staphylococcus aureus (2021, background): “respiratory tract infections, surgical site, prosthetic joint, and cardiovascular infections, as well as nosocomial bacteremia [3].”
Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies (2017, background): “stream infections, osteomyelitis, and complicated skin and deep tissue infections.(1,2) Methicillin-resistant S.”
Bacterial Antibiotic Resistance: The Most Critical Pathogens (2021, background): “aureus causes infections ranging from mild to life-threatening such as skin and soft tissue infections, bacterial endocarditis, pleuropulmonary and device-related infections [69].”
Identification and treatment of the Staphylococcus aureus reservoir in vivo (2016, neutral): “aureus infection have been well documented (Tong et al., 2015).”
Identification of a domain critical for Staphylococcus aureus LukED receptor targeting and lysis of erythrocytes (2020, background): “Staphylococcus aureus is a Gram-positive pathobiont responsible for significant human disease (1).”
Challenges in Infective Endocarditis. (2017, background): “In the United States, 10% to 20% of the population are persistent carriers of S aureus (45).”